Mutants of L-glutamate dehydrogenase and their applications

By mutating amino acid residues at positions 175 and 386 of Lysinibacillus sphaericus glutamate dehydrogenase, the catalytic efficiency for producing L-glufosinate is enhanced, addressing the inefficiencies and high costs of conventional methods.

JP7582974B2Active Publication Date: 2024-11-13SHANGHAI QIZHOU ZIYUE BIOTECHNOLOGY CO LTD
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
JP2021569424
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-05-23
Filing Date
2020-05-12
Publication Date
2024-11-13
Estimated Expiration
2040-05-12

AI Technical Summary

Technical Problem

Conventional methods for producing L-glufosinate suffer from low catalytic efficiency and high production costs due to the limitations of existing glutamate dehydrogenase enzymes, particularly when double mutations at specific sites are unpredictable.

Method used

Mutating the amino acid residues at positions 175 and 386 of Lysinibacillus sphaericus glutamate dehydrogenase to reduce steric hindrance, resulting in a mutant enzyme with enhanced catalytic activity for producing L-glufosinate.

Benefits of technology

The mutant enzyme exhibits higher specific enzymatic activity, reducing reaction costs and improving industrial production efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007582974000012
    Figure 0007582974000012
  • Figure 0007582974000013
    Figure 0007582974000013
  • Figure 0007582974000014
    Figure 0007582974000014
Patent Text Reader

Abstract

The present invention discloses an L-glutamate dehydrogenase mutant. The sequence of the L-glutamate dehydrogenase mutant is a sequence in which the amino acid residue A at position 175 of the sequence set forth in SEQ ID NO: 1 is mutated to G and the amino acid residue V at position 386 is mutated to an amino acid residue with less steric hindrance. The present invention also discloses the use of this L-amino acid dehydrogenase mutant in the preparation of L-glufosinate or a salt thereof. When L-glufosinate or a salt thereof is prepared using the L-glutamate dehydrogenase mutant of the present invention, the specific enzyme activity is higher than that of L-glutamate dehydrogenase mutants mutated only at position 175 or only at position 386, thereby improving the efficiency of enzyme action, reducing reaction costs, and being advantageous for industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This application claims priority from Chinese patent application CN201910434350.1, filed on May 23, 2019. This application incorporates the full text of said Chinese patent application.

[0002] (Technical field) The present invention relates to the field of biotechnology, and specifically to mutants of L-glutamate dehydrogenase and their applications. [Background technology]

[0003] Glufosinate (2-amino-4-[hydroxy(methyl)phosphono]butyric acid) is a broad-spectrum contact herbicide developed by Hearst in the 1980s. Currently, the three major herbicides in the world are glyphosate, glufosinate, and paraquat. Compared to glyphosate and paraquat, glufosinate has superior herbicidal performance and relatively few side effects. Glufosinate has two optical isomers, D-glufosinate and L-glufosinate, but only L-glufosinate has herbicidal activity, so the development of L-glufosinate is of great significance in improving atom economy, reducing costs, and mitigating environmental impact.

[0004] Currently, the main methods for preparing L-glufosinate include chiral resolution, chemical synthesis, and biocatalysis.

[0005] Chiral resolution methods, such as CN1053669C, disclose a method using quinine alkaloids as a resolution agent, recrystallizing the quinine salt of L-glufosinate, and neutralizing the salt with acid to obtain L-glufosinate. At the same time, 5-nitrosalicylaldehyde or 3,5-dinitrosalicylaldehyde is used as a racemization agent to racemize unreacted D-glufosinate to obtain DL-glufosinate, which is then subjected to a resolution reaction. However, this method requires expensive chiral resolution reagents and multi-stage recrystallization, and the operation is complicated, making it not an ideal method. [ka]

[0006] Chemical synthesis methods, such as US6936444, disclose asymmetric hydrogenation of 2-acetylamino-4-(hydroxymethylphosphinyl)-2-butenoic acid with a ruthenium catalyst to obtain L-2-acetylamino-4-(hydroxymethylphosphinyl)-2-butyric acid, which is then deacetylated to obtain L-glufosinate. This method requires an expensive metal catalyst, which is not only costly but also leaves heavy metal residues, causing serious environmental pollution. [ka]

[0007] Compared with chiral resolution and chemical synthesis, the biocatalytic method has the advantages of high specificity and mild reaction conditions, making it an excellent method for producing L-glufosinate.

[0008] Currently, as described in US4389488(A), there is a method of obtaining L-glufosinate using N-phenylacetyl-DL-glufosinate as a substrate and penicillin-G-acyltransferase derived from Escherichia coli as a catalyst; however, the cost of synthesizing phenylacetylglufosinate is relatively high, and after completion of the reaction, a mixed solution of L-glufosinate, N-phenylacetyl-D-glufosinate, and phenylacetic acid must be obtained, and L-glufosinate must be separated using a strong acid cation exchange resin, making the operation complicated. [ka]

[0009] EP0382113A describes a method for obtaining L-glufosinate by catalytically decomposing the carboxylic acid ester of N-acetyl-glufosinate using acyltransferase. However, since the enzyme in this method has no specificity for free N-acetyl-glufosinate, it is necessary to esterify N-acetyl-glufosinate, which increases the number of reaction steps and the production costs accordingly.

[0010] There is also a method of preparing L-glufosinate using 2-oxo-4-(hydroxymethylphosphinyl)butyric acid (PPO) as a substrate with a transaminase catalyst; US5221737A and EP0344683A describe a method of using glutamic acid as an amino donor to obtain L-glufosinate from the corresponding keto acid 4-(hydroxymethylphosphinyl)-2-oxobutyric acid by the action of aminotransaminase derived from Escherichia coli; however, the reaction system requires the same amount or an excess of the amino donor glutamic acid, making it difficult to purify the product. CN1284858C improves the above method, using aspartic acid as an amino donor to obtain L-glufosinate from the corresponding keto acid 4-(hydroxymethylphosphinyl)-2-oxobutyric acid by the action of aspartate transaminase, in which aspartic acid is converted to oxalyl acetate, but since oxalyl acetate is unstable in water-containing media, it is spontaneously decarboxylated to pyruvic acid, and pyruvic acid can be removed by enzyme reaction, so the reverse reaction is impossible, and only equimolar amounts of amino donor and amino acceptor are required for the reaction. However, the amino donor used in the method using transaminase is often an amino acid, which is expensive. [ka]

[0011] There is also a method for preparing L-glufosinate using 2-oxo-4-(hydroxymethylphosphinyl)butyric acid (PPO) as a substrate and amino acid dehydrogenase as a catalyst, such as CN106978453A, which uses an inorganic amino donor to simplify product separation and reduce costs. However, in CN106978453A, the substrate concentration range for the enzyme catalyst is only 10-100 mM, and the catalytic efficiency of the enzyme is not high. [ka]

[0012] CN108588045A disclosed the application of several mutant glutamate dehydrogenases in the preparation of L-glufosinate, and found that the mutation of alanine at position 167 to glycine or valine at position 378 to alanine in glutamate dehydrogenase derived from Pseudomonas Putida (NCBI accession number: NP_742836.1) improved the catalytic ability of the enzyme for PPO. It also studied mutants of the homologous sites at positions 167 and 378 of glutamate dehydrogenase derived from other sources and found that such mutants could also improve the catalytic ability of glutamate dehydrogenase for PPO, but did not study combined mutations of the mutants of the homologous sites of these glutamate dehydrogenase derived from other sources. Furthermore, in this patent application, the above two sites of glutamate dehydrogenase of Pseudomonas Putida were mutated simultaneously, but the increase in enzyme activity of the obtained double mutant was only equivalent to that of a single mutation mutant, and due to the unpredictability of the biological field, it cannot be said that the effect of the double mutation site mutant is necessarily better than that of each single mutation mutant. [Prior art documents] [Patent documents]

[0013] [Patent Document 1] Chinese Patent No. 1053669 [Patent Document 2] U.S. Patent No. 6,936,444 [Patent Document 3] U.S. Patent No. 4,389,488 [Patent Document 4] European Patent Application Publication No. 382113 [Patent Document 5] U.S. Patent No. 5,221,737 [Patent Document 6] European Patent Application Publication No. 344683 [Patent Document 7] China Patent Application Publication No. 106978453 [Patent Document 8] China Patent Application Publication No. 106978453 [Patent Document 9] China Patent Application Publication No. 108588045 DISCLOSURE OF THEINVENTION [Problem to be solved by the invention]

[0014] The technical problem to be solved by the present invention is that conventional L-glutamate dehydrogenase has shortcomings such as low catalytic efficiency in preparing L-glufosinate or a salt thereof, and therefore the present invention provides an L-glutamate dehydrogenase mutant and the application of the L-glutamate dehydrogenase mutant in preparing L-glufosinate or a salt thereof. When preparing L-glufosinate or a salt thereof with the L-glutamate dehydrogenase mutant of the present invention, the specific enzyme activity is higher than that of a glutamate dehydrogenase mutant with a single mutation site (position 175 or 386), which improves the enzyme action efficiency, reduces reaction costs, and is advantageous for industrial production. [Means for solving the problem]

[0015] The wild-type L-glutamate dehydrogenase used in the present invention is derived from the glutamate dehydrogenase of Lysinibacillus sphaericus, and its amino acid sequence is shown in SEQ ID NO: 1, and its Genbank accession number is WP_012293812.1. In the prior art, this glutamate dehydrogenase has not been double-mutated at two sites at the same time, and due to the unpredictability of the biological field, the effect of the mutant with the double mutation site is not necessarily better than that of each single mutation mutant. The inventors have unexpectedly found that, when the wild-type enzyme is mutated at positions 175 and 386 in combination with respect to the substrate 2-oxo-4-(hydroxymethylphosphinyl)butyric acid (PPO), the specific enzyme activity of the resulting mutant for the substrate PPO is greatly increased after the amino acid residue A at position 175 is mutated to G and the amino acid residue V at position 386 is mutated to an amino acid residue with less steric hindrance.

[0016] One of the technical aspects of the present invention for solving the above technical problem is a mutant L-glutamate dehydrogenase having the activity of catalytically catalyzing 2-oxo-4-(hydroxymethylphosphinyl)butyric acid or a salt thereof, which is a sequence in which the amino acid residue A at position 175 of the sequence set forth in SEQ ID NO:1 is mutated to G and the amino acid residue V at position 386 is mutated to an amino acid residue with less steric hindrance.

[0017] Preferably, the amino acid sequence of the mutant L-glutamate dehydrogenase is as shown in SEQ ID NO: 7 or SEQ ID NO: 9 in the sequence listing.

[0018] Preferably, the nucleotide sequence of the mutant L-glutamate dehydrogenase is as shown in SEQ ID NO:8 or SEQ ID NO:10 in the sequence listing.

[0019] According to the present invention, the less steric hindrance means that the mutated amino acid residue is less sterically hindered than the amino acid residue in the wild-type sequence. The amino acid may be a modified or unmodified natural amino acid. The present invention takes natural amino acids as an example.

[0020] The second technical aspect of the present invention for solving the above technical problem is an isolated nucleic acid encoding the mutant of L-glutamate dehydrogenase.

[0021] Preferably, the nucleotide sequence encoding said nucleic acid is as shown in SEQ ID NO:8 or SEQ ID NO:10.

[0022] The third technical aspect of the present invention for solving the above technical problem is a recombinant expression vector containing the nucleic acid.

[0023] A fourth technical aspect of the present invention for solving the above technical problem is a transformant comprising the nucleic acid or the recombinant expression vector.

[0024] A fifth technical aspect of the present invention for solving the above technical problems is a method for preparing L-glufosinate salt, which includes a step of ammonifying 2-oxo-4-(hydroxymethylphosphinyl)butyrate in the presence of a reaction solvent, a mutant of L-glutamate dehydrogenase, an inorganic amino donor, and reduced coenzyme NADPH (nicotinamide adenine dinucleotide phosphate) to obtain L-glufosinate salt.

[0025] In the above preparation method, except that the mutant of L-glutamate dehydrogenase is obtained by the present invention, the other raw materials, reaction steps and conditions are all conventional in the art, specifically see CN106978453A and the applicant's patent application with application number CN201810162629.4.

[0026] The method for preparing the L-glufosinate salt further includes a step of oxidizing the D-glufosinate salt in the presence of D-amino acid oxidase (DAAO) to obtain the 2-oxo-4-(hydroxymethylphosphinyl)butyrate.

[0027] In the oxidation reaction, the cation of the D-glufosinate salt may be a conventional cation in the art, such as an ammonium ion, a sodium ion, and / or a potassium ion, etc. It may also be a cation of the buffer used.

[0028] In the oxidation reaction, the D-glufosinate salt may be present alone or together with an L-glufosinate salt (in which case the L-glufosinate salt does not need to react), and may be, for example, a D-enantiomer-enriched glufosinate salt (i.e., D-enantiomer content >50%, thus pure D-glufosinate salt), an L-enantiomer-enriched glufosinate salt (i.e., L-glufosinate content >50%, excluding the case of pure L-glufosinate salt), or a racemic glufosinate salt.

[0029] In the oxidation reaction, the concentration of the D-amino acid oxidase (DAAO) may be any conventional concentration in the art, preferably 0.6-6 U / ml, more preferably 1.8 U / ml.

[0030] In the oxidation reaction, the concentration of the D-glufosinate salt may be any conventional concentration in the art, preferably 100 to 600 mM, more preferably 200 mM. The oxidation reaction may be carried out in the presence of catalase.

[0031] The oxidation reaction may be carried out under aeration conditions. The aeration is preferably the introduction of air or oxygen. The aeration rate is preferably 0.5 to 1 VVM.

[0032] In the present invention, the air can be the conventional air in the art, generally contains oxygen, and the content of oxygen contained is also the conventional content in the art. When reacting, it is the oxygen in the air that participates in the reaction.

[0033] When the oxidation reaction is carried out under aeration conditions, the oxidation reaction may be carried out in the presence of an antifoaming agent.

[0034] In the oxidation reaction, the pH of the reaction system is preferably 7 to 9, and more preferably 8. The pH can be achieved by a buffer solution. The pH can also be achieved by adjusting the pH with an alkali (or an alkaline solution). The buffer solution is preferably a phosphate buffer solution or a Tris-HCl buffer solution, and the phosphate buffer solution is preferably a disodium hydrogen phosphate-sodium dihydrogen phosphate buffer solution or a dipotassium hydrogen phosphate-potassium dihydrogen phosphate buffer solution. The alkaline solution is preferably ammonia.

[0035] In the oxidation reaction, the temperature of the reaction system may be any temperature conventional in this field, preferably 20 to 50°C, more preferably 20°C.

[0036] The oxidation reaction and the ammonification reaction may proceed separately or simultaneously (in the same reaction system). The simultaneous proceeding may be, for example, by subjecting D-glufosinate salt to an oxidation reaction and an ammonification reaction in the presence of D-amino acid oxidase (DAAO), a mutant of L-glutamate dehydrogenase, an inorganic amino donor, and a reduced coenzyme NADPH to obtain L-glufosinate salt.

[0037] In the ammonification reaction, the cation of the L-glufosinate salt may be a conventional cation in the art, such as ammonium ion, sodium ion, and / or potassium ion, etc. It may also be a cation of the buffer used.

[0038] In the ammonification reaction, the cation of the 2-oxo-4-(hydroxymethylphosphinyl)butyrate salt may be a conventional cation in the art, such as ammonium ion, sodium ion, and / or potassium ion, etc. It may also be the cation of the buffer solution used.

[0039] The above amino In the polymerization reaction, the dosage of the mutant L-glutamate dehydrogenase may be conventional in the art, and the concentration of the mutant L-glutamate dehydrogenase is preferably 0.05 to 1.005 mg / L. 3 U / ml, more preferably 0.1 to 1 U / ml, for example 0.23 U / ml.

[0040] In the ammonification reaction, the dosage of the inorganic amino donor may be conventional in the art, and the concentration of the inorganic amino donor is preferably 100-2000 mM, more preferably 200 mM.

[0041] In the ammonification reaction, the concentration of the 2-oxo-4-(hydroxymethylphosphinyl)butyrate is preferably 100 to 600 mM, and more preferably 200 mM.

[0042] In the ammonification reaction, the dosage of the 2-oxo-4-(hydroxymethylphosphinyl)butyrate may be conventional in the art, and the mass ratio of the reduced coenzyme NADPH to the 2-oxo-4-(hydroxymethylphosphinyl)butyrate is preferably 1:100 to 1:20000, more preferably 1:1000 to 1:15000, and even more preferably 1:5000.

[0043] In the ammonification reaction, the inorganic amino donor is one or more of ammonia, ammonium sulfate, ammonium chloride, diammonium hydrogen phosphate, ammonium acetate, ammonium formate, and ammonium bicarbonate.

[0044] In the ammonification reaction, the reaction temperature may be any conventional one in the art. In order to ensure the catalytic efficiency of the L-glutamate dehydrogenase mutant, the ammonification reaction is preferably carried out at a temperature of 20-50°C, more preferably 37°C. If the ammonification reaction temperature is below 20°C, the ammonification reaction is slow, and if the ammonification reaction temperature is above 50°C, the enzyme will be irreversibly denatured and inactivated.

[0045] In the ammonification reaction, the reaction solvent is water.

[0046] In the preparation method, the pH at which the ammonification reaction is carried out is preferably 7 to 9, more preferably 8.5. The pH can be achieved by a buffer solution. The pH can also be achieved by adjusting with an alkali (or an alkaline solution). The buffer solution is preferably a phosphate buffer solution or a Tris-HCl buffer solution, and the phosphate buffer solution is preferably a disodium hydrogen phosphate-sodium dihydrogen phosphate buffer solution or a dipotassium hydrogen phosphate-potassium dihydrogen phosphate buffer solution. The alkaline solution is preferably ammonia.

[0047] The method for preparing the L-glufosinate salt comprises reacting the oxidized coenzyme NADP in the presence of a dehydrogenase (e.g., glucose dehydrogenase, alcohol dehydrogenase, or formate dehydrogenase) and a hydrogen donor (e.g., glucose, isopropanol, or formate salt). + by reducing reaction to obtain the reduced coenzyme NADPH.

[0048] In the reduction reaction, the dehydrogenase and the hydrogen donor correspond to each other in a one-to-one relationship, For example, when the dehydrogenase is an alcohol dehydrogenase, the hydrogen donor is isopropanol; When the dehydrogenase is glucose dehydrogenase, the hydrogen donor is glucose; When the dehydrogenase is formate dehydrogenase, the hydrogen donor is formate.

[0049] In the reduction reaction, the concentration of the dehydrogenase may be any concentration conventional in the art, preferably 0.6 to 6 U / ml, more preferably 2 U / ml.

[0050] In the reduction reaction, the concentration of the hydrogen donor may be conventional in the art, preferably 100-1000 mM, more preferably 240 mM.

[0051] In the reduction reaction, the oxidized coenzyme NADP + The concentrations may be conventional in the art.

[0052] In the reduction reaction, the pH at which the reduction reaction is carried out is preferably 7 to 9, and more preferably 8.5. The pH can be achieved by a buffer solution. The pH can also be achieved by adjusting the pH with an alkali (or an alkaline solution). The buffer solution is preferably a phosphate buffer solution or a Tris-HCl buffer solution, and the phosphate buffer solution is preferably a disodium hydrogen phosphate-sodium dihydrogen phosphate buffer solution or a dipotassium hydrogen phosphate-potassium dihydrogen phosphate buffer solution. The alkaline solution is preferably ammonia.

[0053] In the reduction reaction, the temperature of the reaction system may be any temperature conventional in this field, preferably 20 to 50°C, more preferably 37°C.

[0054] The reduction reaction and the ammonification reaction may proceed separately or simultaneously (in the same reaction system). The simultaneous proceeding may be, for example, as shown in a preferred embodiment of the present invention, in which glucose dehydrogenase, glucose, and the oxidized coenzyme NADP + In the presence of a mutant form of L-glutamate dehydrogenase and an inorganic amino donor, 2-oxo-4-(hydroxymethylphosphinyl)butyrate was reacted with NADP+ (reduction reaction) to obtain L-glufosinate salt.

[0055] When the reduction reaction and the ammonification reaction proceed simultaneously, the NADPH used in the ammonification reaction is repeatedly produced by the reduction reaction. + may be conventional in the art, and the mass ratio of it to the 2-oxo-4-(hydroxymethylphosphinyl)butyrate is 1:100-1:20000, preferably 1:1000-1:15000, more preferably 1:5000, to ensure that the reaction can proceed normally.

[0056] The reduction reaction, the oxidation reaction, and the ammonification reaction may proceed separately or simultaneously (in the same reaction system). For example, as shown in a preferred embodiment of the present invention, the simultaneous proceedings may involve the simultaneous reactions of D-amino acid oxidase (DAAO), dehydrogenase, a hydrogen donor, and an oxidized coenzyme NADP. + In the presence of L-glutamate dehydrogenase mutants and inorganic amino donors, D-glufosinate salt was oxidized and ammonified (NADP + (reduction reaction) to obtain L-glufosinate salt.

[0057] When the reduction reaction, the oxidation reaction, and the ammonification reaction proceed simultaneously, the NADPH used in the ammonification reaction is repeatedly produced by the reduction reaction. + The concentration of NADP may be conventional in the art to ensure that the reaction can proceed normally. + and the 2-oxo-4-(hydroxymethylphosphinyl)butyrate salt has a mass ratio of 1:100 to 1:20000, preferably 1:1000 to 1:15000, and more preferably 1:5000.

[0058] The reaction time of the preparation method may be terminated when the final concentration of the raw material or the final concentration of the product or the conversion rate reaches a desired target, as detected by a conventional method, such as pre-column derivatization high performance liquid chromatography or ion pair chromatography.

[0059] A sixth technical aspect of the present invention for solving the above technical problem is a method for preparing L-glufosinate, comprising the following steps: (1) Prepare L-glufosinate salt by the above-mentioned method for preparing L-glufosinate salt. (2) The L-glufosinate salt obtained in step (1) is subjected to an oxidation reaction to obtain L-glufosinate.

[0060] The seventh technical aspect of the present invention for solving the above technical problems is the application of the above prepared L-glutamate dehydrogenase mutant in the preparation of L-glufosinate or a salt thereof.

[0061] The application may include reacting 2-oxo-4-(hydroxymethylphosphinyl)butyrate in the presence of L-amino acid dehydrogenase, an inorganic amino donor, and a reduced coenzyme to obtain L-glufosinate salt.

[0062] Alternatively, the application may include a step of reacting 2-oxo-4-(hydroxymethylphosphinyl)butyric acid in the presence of L-amino acid dehydrogenase, an inorganic amino donor, and a reduced coenzyme to obtain L-glufosinate.

[0063] Alternatively, the application may include a step of reacting 2-oxo-4-(hydroxymethylphosphinyl)butyrate in the presence of L-amino acid dehydrogenase, an inorganic amino donor, and a reduced coenzyme to obtain L-glufosinate salt, which is then further oxidized to obtain L-glufosinate.

[0064] In the present invention, the L-glufosinate salt may generally be present in the form of an L-glufosinate ammonium salt.

[0065] Unless otherwise specified, the concentrations of the above compounds are the concentrations of the compounds in the entire reaction system before the reaction.

[0066] Based on common knowledge in this field, each of the above preferred conditions can be arbitrarily combined to obtain each of the preferred embodiments of the present invention.

[0067] All reagents and materials used in the present invention are commercially available. Effect of the Invention

[0068] The positive and progressive effects of the present invention are: When L-glufosinate or a salt thereof is prepared using the L-glutamate dehydrogenase mutant of the present invention, the specific enzymatic activity is higher than that of a glutamate dehydrogenase mutant having a single mutation site (position 175 or 386), which improves the efficiency of the enzyme's action (e.g., when involved in a reaction, the conversion rate is higher and the stereoselectivity is stronger), reduces the reaction cost, and is advantageous for industrial production. [Brief description of the drawings]

[0069] [Figure 1] Figure 1 shows the HPLC analysis result of racemic glufosinate standard pre-column derivatization with Marfey's reagent, and the last two peaks are those of Marfey's reagent itself. [Diagram 2] FIG. 2 shows the HPLC analysis results of D-glufosinate and L-glufosinate in the prepared product after precolumn derivatization with Marfey's reagent. [Diagram 3] FIG. 3 shows the results of ion-pair HPLC analysis of a racemic glufosinate standard. [Figure 4] FIG. 4 shows the results of ion-pair HPLC analysis of a PPO standard sample. [Diagram 5] FIG. 5 shows the results of ion-pair HPLC analysis of the reaction solution after the reaction. [Figure 6]FIG. 6 shows the mass spectrum of a standard PPO sample. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0070] The present invention will be further described below in the form of examples, but the present invention is not limited to the scope of the above examples. In the following examples, experimental methods without specific conditions are selected according to conventional methods or conditions, or according to product instructions.

[0071] Unless otherwise specified, the experimental methods used in the present invention are conventional methods, and the gene cloning procedures can be specifically referred to "Molecular Cloning: A Laboratory Manual" edited by J. Sambrook et al.

[0072] The amino acid abbreviations used herein are those conventional in the art unless otherwise specified, and the amino acids corresponding to the specific abbreviations are shown in Table 1.

[0073] [Table 1]

[0074] The codons corresponding to the above amino acids are also conventional in the art, and the correspondence between specific amino acids and codons is shown in Table 2.

[0075] [Table 2]

[0076] pET28a was purchased from Novagen, NdeI enzyme, HindIII enzyme were purchased from Thermo Fisher, E. coli BL21(DE3) competent cells were purchased from Beijing Dingguo Changsheng Biological Technology Co., Ltd., catalase was purchased from Shandong Fengtai Biological Technology Co., Ltd., NADPH was purchased from Shenzhen Bangtai Biological Engineering Co., Ltd., and NH4Cl was purchased from Shanghai Taitan Technology Co., Ltd.

[0077] Chiral analysis of the product was carried out by pre-column derivatization high performance liquid chromatography (HPLC), and the specific analytical method is as follows. (1) Chromatography conditions: Agilent ZORBAX Eclipse plus C18, 3.5μm, 150 * 4.6 mm. Mobile phase A: 0.1% TFA + H2O, Mobile phase B: 0.1% TFA + CAN. Detection wavelength: 340 nm, Flow rate: 1.0 ml / min, Column temperature: 30°C. (2) Derivatization reagent: Marfey's Reagent: 50 mg of N-α-(2,4-dinitro-5-fluorophenyl)-L-alaninamide was accurately weighed and dissolved in acetonitrile to prepare 25 ml of solution. (3) Derivatization reaction: The reaction mixture was diluted 100-fold and derivatized by adding an equal volume of Marfey's reagent. 10 μl of sample was injected and analyzed.

[0078] Conversion rate = (reactants - remaining reactants) / reactants x 100%

[0079] 2-Oxo-4-(hydroxymethylphosphinyl)butyric acid (abbreviated as PPO) was analyzed by ion-pair high performance liquid chromatography (HPLC), and the specific analysis method is as follows.

[0080] Chromatography conditions: ULtimate AQ-C18, 5μm, 4.6 * 250 mm; mobile phase: 0.05 mol / L diammonium hydrogen phosphate pH = 3.6 : 10% aqueous tetrabutylammonium hydroxide : acetonitrile = 91:1:8; detection wavelength: 205 nm; flow rate: 1.0 ml / min; column temperature: 25 °C.

[0081] In the following examples, "glufosinate" is written in all cases, but since "glufosinate" is in the reaction system, those skilled in the art would call "glufosinate ammonium salt" "glufosinate", so "glufosinate" actually refers to "glufosinate ammonium salt", and the corresponding glufosinate standards are also glufosinate ammonium salt standards, and the corresponding produced PPO is also PPO ammonium salt. When detecting the optical rotation of the resulting product glufosinate, the glufosinate ammonium salt was subjected to an oxidation reaction, and then detection was performed after obtaining glufosinate. EXAMPLES

[0082] (Example 1) Obtaining mutant enzymes of L-glutamate dehydrogenase

[0083] The sequence of Lysinibacillus sphaericus-derived glutamate dehydrogenase (hereinafter referred to as LsGluDH) (SEQ ID NO: 1, Genbank accession number WP_012293812.1) was searched from NCBI, and the gene was synthesized based on the nucleotide sequences of the mutant genes in Table 3 (SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10). The gene synthesis company was Suzhou Jinweizhi Bio-Technology Co., Ltd. (C3F, Bio-Nami Science and Technology Park, No. 218 Xinghu Street, Suzhou Industrial Park).

[0084] Then, the mutant genes were enzymatically ligated into pET28a, respectively, with the enzyme cleavage sites being NDEI & HINDIII. The enzymatically ligated vectors were transformed into host E. coli BL21 competent cells. The constructed strains were inoculated into TB medium at 37°C, shaken at 200 rpm, and induced overnight with IPTG at a concentration of 0.1 mM, and the bacteria were collected to obtain the engineering bacteria containing the glutamate dehydrogenase gene.

[0085] After activating the engineered strain containing the glutamate dehydrogenase gene by plate-streaking, a single colony was inoculated into 5 ml of LB liquid medium containing 50 μg / ml kanamycin and cultured at 37°C for 12 hours with shaking. A 2% inoculum was inoculated into 150 ml of fresh LB liquid medium also containing 50 μg / ml kanamycin and cultured at 37°C until OD 600 The mixture was shaken until the pH reached about 0.8, IPTG was added to a final concentration of 0.5 mM, and induction culture was carried out for 16 hours at 18°C. After the culture was completed, the culture solution was centrifuged at 10,000 rpm for 10 minutes, the supernatant was discarded, and the bacteria were collected and stored in a cryogenic refrigerator at -80°C.

[0086] Five grams of the collected bacteria were washed twice with 50 mm pH 8.5 Tris-HCl buffer, suspended in 30 ml pH 8.5 Tris-HCl buffer, and homogenously disrupted. The disrupted solution was centrifuged at 12,000 rpm for 10 minutes to remove the precipitate, and a crude enzyme solution was obtained as the supernatant containing the recombinant glutamate dehydrogenase.

[0087] [Table 3] Example 2: Detection of specific enzyme activity of mutant enzymes

[0088] Preparation of substrate solution: 355 μl of 2.25 M PPO (final concentration 20 mM) (prepared by the inventors; the preparation method is described in US8017797B, and Figure 6 shows the corresponding mass spectrum) and 0.4 g of NH4Cl (final concentration 200 mM) were added, the pH was adjusted to 8.5 with ammonia, and the volume was adjusted to 40 ml with 50 mM pH 8.5 Tris-HCl buffer.

[0089] Methods for detecting enzyme activity: The total reaction system was 1 ml, and the absorbance value at OD340 nm was measured. 940 μl of substrate solution was added to the 1 ml cell in sequence, and after resetting to zero, 10 μl of 25 mm NADPH was added, and finally 50 μl of crude enzyme solution was added. The changes in the values ​​from 0 to 10 minutes were recorded, and the values ​​were read every 30 seconds. The reaction time was plotted as the abscissa and the absorbance value at a wavelength of 340 nm as the ordinate. The slope was measured to calculate the rate of decrease of NADPH and the enzyme activity.

[0090] Definition of unit enzyme activity: The amount of enzyme required to reduce 1 μmol of NADPH per minute under specific reaction conditions (30°C).

[0091] The specific enzyme activity is the unit of activity contained in 1 mg of enzyme protein, and is calculated as follows: enzyme activity / protein content, with the unit being U / mg or U / g. The results are shown in Table 4.

[0092] As can be seen from CN108588045A, the enzyme activity of the wild-type LsGluDH-WT (WP_012293812.1) is much lower than that of the single-site mutant, and those skilled in the art can conclude that the specific enzyme activity of the wild-type LsGluDH-WT (WP_012293812.1) is also much lower than that of the mutant, so that it was not detected against the wild-type LsGluDH-WT (WP_012293812.1) in the present invention.

[0093] [Table 4]

[0094] The L-glutamate dehydrogenase crude enzyme solutions used in the following Examples were all prepared according to the above method.

[0095] (Example 3) Acquisition of D-amino acid oxidase (DAAO) gene

[0096] The DAAO enzyme gene was fully synthesized according to the gene sequence of AC302 DAAO enzyme described in patent US9834802B2. The synthesis company is Suzhou Jinweizhi Biotechnology Co., Ltd., No. 211 Pubin Road, Research and Development Park, Jiangbei New Area, Nanjing City, Jiangsu Province.

[0097] Example 4: Expression of D-amino acid oxidase (DAAO) gene

[0098] Composition of LB liquid medium: Peptone 10 g / L, yeast powder 5 g / L, and NaCl 10 g / L were dissolved in deionized water, adjusted to the specified volume, and sterilized at 121° C. for 20 minutes.

[0099] The DAAO enzyme gene synthesized in Example 3 was ligated into pET28a, with the enzyme cleavage sites being DneI & HindIII, and the enzyme-ligated vector was transformed into host E. coli BL21(DE3) competent cells to obtain an engineered strain containing the DAAO enzyme.

[0100] After activating the engineered strain containing the DAAO enzyme gene by streak plating, a single colony was inoculated into 5 ml of LB liquid medium containing 50 μg / ml kanamycin and cultured at 37°C for 12 hours with shaking. A 2% inoculum was inoculated into 50 ml of fresh LB liquid medium also containing 50 μg / ml kanamycin and cultured at 37°C until OD 600 The mixture was shaken until the pH reached about 0.8, IPTG was added to a final concentration of 0.5 mM, and induction culture was carried out for 16 hours at 18°C. After the culture was completed, the culture solution was centrifuged at 10,000 rpm for 10 minutes, the supernatant was discarded, and the bacteria were collected and stored in a cryogenic refrigerator at -20°C.

[0101] (Example 5) Preparation of D-amino acid oxidase (DAAO) crude enzyme solution and enzyme activity measurement

[0102] The cells collected in Example 4 were washed twice with 50 mm pH 8.0 phosphate buffer, then suspended in pH 8.0 phosphate buffer and homogenously disrupted at low temperature and high pressure. The disrupted solution was centrifuged to remove the precipitate, and the resulting supernatant was a crude enzyme solution containing the recombinant DAAO enzyme.

[0103] Methods for detecting enzyme activity: 100 μl pH 8.0 disodium hydrogen phosphate-sodium dihydrogen phosphate buffer (containing 50 mmol / L D-glufosinate and 0.1 mg / ml peroxide enzyme), 50 μl color developer (60 μg / ml 2,4,6-tribromo-3-hydroxybenzoic acid and 1 mg / ml 4-aminoantipyrine), and 50 μl DAAO enzyme were added, and the H2O2 concentration was measured by detecting ultraviolet absorption at 510 nm, and the PPO concentration and enzyme activity were calculated.

[0104] Definition of unit enzyme activity: This is the amount of enzyme required to produce 1 μmol PPO per minute under specific reaction conditions (30°C).

[0105] The above method is used to prepare the DAAO enzyme crude enzyme solution used in the following examples.

[0106] (Example 6) Acquisition and expression of alcohol dehydrogenase gene

[0107] The alcohol dehydrogenase gene was completely synthesized according to the cyclopentanol dehydrogenase gene sequence derived from Lactobacillus brevis KB290 (Genbank accession number BAN05992.1).

[0108] Composition of LB liquid medium: Peptone 10 g / L, yeast powder 5 g / L, and NaCl 10 g / L were dissolved in deionized water, adjusted to the specified volume, and sterilized at 121° C. for 20 minutes.

[0109] The alcohol dehydrogenase gene was ligated into pET28a, the enzyme cleavage sites were NdeI & HindIII, and the enzyme-ligated vector was transformed into host E. coli BL21(DE3) competent cells to obtain an engineered strain containing the alcohol dehydrogenase gene. After activating the engineered strain containing the alcohol dehydrogenase gene by streak plating, a single colony was inoculated into 5 ml LB liquid medium containing 50 μg / ml kanamycin and cultured at 37°C for 12 hours with shaking. 2% inoculum was inoculated into 50 ml of fresh LB liquid medium also containing 50 μg / ml kanamycin and cultured at 37°C for 12 hours with shaking. 600 The mixture was shaken until the pH reached about 0.8, IPTG was added to a final concentration of 0.5 mM, and induction culture was carried out for 16 hours at 18°C. After the culture was completed, the culture solution was centrifuged at 10,000 rpm for 10 minutes, the supernatant was discarded, and the bacteria were collected and stored in a cryogenic refrigerator at -20°C.

[0110] (Example 7) Preparation of crude alcohol dehydrogenase enzyme solution and enzyme activity measurement

[0111] The bacteria collected in Example 6 were added to 50 ml of 100 mm pH 7.5 ammonium phosphate buffer, stirred uniformly, and homogenously disrupted at 500 bar to obtain a crude enzyme solution. While stirring, 10% flocculant (final concentration 2-2.5‰) was added dropwise, stirred for 5 minutes, and then centrifuged at 4000 rpm for 10 minutes to obtain a supernatant enzyme solution. The supernatant was removed and the enzyme activity was measured.

[0112] Methods for detecting enzyme activity: In a 3 ml reaction system, 2850 μl of 400 mM isopropanol (prepared as 100 mM phosphate buffer) at pH 8.0 was added at 25°C, and then 50 μl of NADP + (25 mM) was added, the UV spectrophotometer was set to zero, and 100 μl of a 100-fold diluted enzyme solution was added, and the OD value at 340 nm was measured using the UV spectrophotometer.

[0113] Definition of unit enzyme activity: 1 U is defined as the amount of enzyme required to produce 1 μmol of NADPH per minute under specific reaction conditions (25°C, pH 7.0).

[0114] The above-mentioned method is employed as a method for preparing the crude alcohol dehydrogenase enzyme solutions used in the following Examples.

[0115] Example 8 Preparation of L-glufosinate catalyzed by DAAO enzymes and mutants of L-glutamate dehydrogenase

[0116] 200 g of L-glutamate dehydrogenase mutant bacteria (prepared according to Example 1) was suspended in 50 mM phosphate buffer (pH 8.0), the volume was adjusted to 1 L, homogenized at low temperature and high pressure, centrifuged, the precipitate was discarded, and the supernatant was retained to obtain a crude enzyme solution of L-glutamate dehydrogenase mutant.

[0117] 80 g of D,L-glufosinate was weighed and completely dissolved in 50 mm pH 8.0 disodium hydrogen phosphate-sodium dihydrogen phosphate buffer, 2.5 g 400,000 U / g catalase was added, 150 ml of the DAAO enzyme crude enzyme solution (12 U / ml) prepared by the method of Example 5 was added, the pH was adjusted to 8.0 with ammonia, and the volume was adjusted to 1 L with 50 mm pH 8.0 disodium hydrogen phosphate-sodium dihydrogen phosphate buffer. The reaction was mechanically stirred in a water bath at 20 ° C, air was passed through at 1 VVM (1 reaction volume of air was passed per minute), 1 ml of antifoam was added to prevent foaming, and the PPO production concentration was detected by ion pair HPLC, and at the same time, the amount and ee value of the remaining L-glufosinate were detected by pre-column derivatization high performance liquid chromatography, and the reaction was stopped when the ee value exceeded 99%.

[0118] Divide the reaction mixture into 4 equal parts (50 ml) and add 0.54 g of ammonium chloride and NADP +0.4 mg of L-glufosinate and 0.73 g of isopropanol were added, 1 ml of alcohol dehydrogenase (300 U / ml) prepared by the method in Example 7 was added, and 1 ml of each crude enzyme solution of the L-glutamate dehydrogenase mutant was added. The pH was adjusted to 8.5 with ammonia water, and the reaction temperature was controlled at 37°C with magnetic stirring in a water bath. The residual PPO concentration was detected by ion-pair HPLC, and at the same time, the amount and ee value of L-glufosinate in the system were detected by pre-column derivatization high-performance liquid chromatography. The data at the end of the reaction are shown in Table 5.

[0119] The HPLC analysis results of D-glufosinate and L-glufosinate in the product after the end of the reaction (18 hours) are shown in Figure 2 (the figure shows the L-glutamate dehydrogenase mutant 1-4 (LsGluDH-A166G-V376A) as an example), except that the retention time is 13.820 minutes for L-glufosinate, and D-glufosinate with a retention time of 12.469 minutes was hardly detected. The Marfey reagent pre-column derivatization HPLC of racemic glufosinate standard (purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.) is shown in Figure 1 (the retention time of L-glufosinate is 13.683 minutes, and the retention time of D-glufosinate is 12.016 minutes). The time at which the peak of L-glufosinate appears in the components of the product prepared in this example and the standard product is almost the same. The resulting product was then oxidized, concentrated, purified by column chromatography, and recrystallized to obtain pure L-glufosinate, which was then identified as [a]D by optical rotation measurement. 25 = +28.2° (C=1, 1N HCl) (the L-glufosinate optical rotation is described in the prior art in US4389488), indicating that L-glufosinate was obtained in this example.

[0120] The ion-pair HPLC analysis result of the reaction solution after the reaction was completed (18 hours) is shown in FIG. 5, except that no peak was observed at the peak position of PPO, and 3.828 minutes was the peak position of glufosinate. The ion-pair HPLC of the PPO standard (this standard is the inventor's own work, and the preparation method is referred to in the literature US8017797B, and FIG. 6 is the corresponding mass spectrum) is shown in FIG. 4, except that the retention time of the PPO standard was 9.520 minutes. The ion-pair HPLC of the racemic glufosinate standard (purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.) is shown in FIG. 3, except that the retention time of the racemic glufosinate standard was 3.829 minutes. Thus, in this example, PPO was finally reacted and completely converted, and the time at which the peak of its product, glufosinate, appeared was almost the same as the time at which the peak of the standard appeared.

[0121] The above result diagrams show the L-glutamate dehydrogenase mutant 1-4 (LsGluDH-A166G-V376A) as an example, but the inventors have conducted experiments on all other mutations and verified that all of these mutations of the present invention can catalyze the substrate when involved in the above reaction, and all of them produce the correct product.

[0122] [Table 5]

[0123] (Comparative Example)

[0124] The mutant enzyme of glutamate dehydrogenase (hereinafter referred to as PpGluDH) of Pseudomonas Putida (Genbank accession number: NP_742836.1) disclosed in CN108588045A was obtained by the same method as in Example 1, and the specific enzyme activity was measured by the method described in Example 2, and the results are shown in Table 6.

[0125] [Table 6]

[0126] From Table 6, it can be seen that the mutants in which the homologous sites of glutamate dehydrogenase derived from Pseudomonas Putida were mutated had significantly lower specific enzyme activity than the mutants obtained in the present invention, and the effects of all double-site mutants were not superior to those of single-mutation mutants.

Claims

1. A mutant of L-glutamate dehydrogenase, The mutant L-glutamate dehydrogenase has an amino acid sequence as set forth in SEQ ID NO:7 or SEQ ID NO:9 in the sequence listing.

2. An isolated nucleic acid encoding a mutant of L-glutamate dehydrogenase according to claim 1.

3. The isolated nucleic acid described in claim 2, characterized in that the sequence of the isolated nucleic acid is as shown in SEQ ID NO: 8 or SEQ ID NO: 10 of the sequence listing.

4. A recombinant expression vector comprising the nucleic acid of claim 2 or 3.

5. A transformant comprising the nucleic acid according to claim 2 or 3 or the recombinant expression vector according to claim 4.

6. A method for preparing an L-glufosinate salt, comprising the step of aminating 2-oxo-4-(hydroxymethylphosphinyl)butyrate in the presence of a reaction solvent, the mutant of L-glutamate dehydrogenase according to claim 1, an inorganic amino donor, and reduced coenzyme NADPH to obtain an L-glufosinate salt.

7. The method for preparing an L-glufosinate salt according to claim 6, further comprising the step of oxidizing a D-glufosinate salt in the presence of a D-amino acid oxidase to obtain the 2-oxo-4-(hydroxymethylphosphinyl)butyrate salt.

8. The D-glufosinate salt exists alone or together with an L-glufosinate salt, and the form that exists together with the L-glufosinate salt is a D-enriched glufosinate salt, an L-enriched glufosinate salt, or a racemic glufosinate salt, and / or The concentration of the D-amino acid oxidase is 0.6 to 6 U / ml; and / or The oxidation reaction is carried out under aeration conditions, and / or The oxidation reaction is carried out in the presence of catalase, and / or The concentration of the D-glufosinate salt is 100 to 600 mM, and / or The pH of the reaction system of the oxidation reaction is 7 to 9, and / or The preparation method according to claim 7, characterized in that the temperature of the reaction system of the oxidation reaction is 20 to 50°C.

9. The concentration of the D-amino acid oxidase is 1.8 U / ml, and / or The aeration is the introduction of air or oxygen, and / or the rate of the aeration is between 0.5 and 1 VVM, and / or The concentration of the D-glufosinate salt is 200 mM; and / or The pH of the reaction system of the oxidation reaction is 8.0, and / or 9. The method according to claim 8, wherein the reaction temperature of the oxidation reaction is 20°C.

10. The concentration of the L-glutamate dehydrogenase mutant is 0.05-3 U / ml; and / or the concentration of the inorganic amino donor is 100-2000 mM; and / or the concentration of the 2-oxo-4-(hydroxymethylphosphinyl)butyrate is 100-600 mM; and / or The mass ratio of the reduced coenzyme NADPH to the 2-oxo-4-(hydroxymethylphosphinyl)butyrate is 1:100 to 1:20000, and / or the inorganic amino donor is one or more of ammonia, ammonium sulfate, ammonium chloride, diammonium hydrogen phosphate, ammonium acetate, ammonium formate, and ammonium bicarbonate; and / or the reaction solvent is water, and / or The pH of the reaction system of the amination reaction is 7 to 9, and / or The preparation method according to any one of claims 6 to 9, characterized in that the temperature of the reaction system of the amination reaction is 20 to 50°C.

11. In the presence of dehydrogenase and a hydrogen donor, the oxidized coenzyme NADP + The method according to any one of claims 6 to 10, further comprising a step of reducing the coenzyme NADPH.

12. The method of claim 11, wherein the dehydrogenase is glucose dehydrogenase, alcohol dehydrogenase, or formate dehydrogenase, and / or the hydrogen donor is glucose, isopropanol, or formate.

13. The method of claim 12, wherein the hydrogen donor is isopropanol when the dehydrogenase is an alcohol dehydrogenase, the hydrogen donor is glucose when the dehydrogenase is glucose dehydrogenase, and the hydrogen donor is formate when the dehydrogenase is formate dehydrogenase.

14. The concentration of the dehydrogenase is between 0.6 and 6 U / ml; and / or The oxidized coenzyme NADP + and the mass ratio of said 2-oxo-4-(hydroxymethylphosphinyl)butyrate is from 1:100 to 1:20000; and / or The concentration of the hydrogen donor is 100 to 1000 mM; and / or The pH of the reaction system of the reduction reaction is 7 to 9, and / or The preparation method according to any one of claims 11 to 13, characterized in that the temperature of the reaction system in the reduction reaction is 20 to 50°C.

15. (1) preparing an L-glufosinate salt by the preparation method according to any one of claims 6 to 14; and (2) A method for preparing L-glufosinate, comprising: subjecting the L-glufosinate salt obtained in step (1) to an oxidation reaction to obtain L-glufosinate.

16. A mutant of L-glutamate dehydrogenase according to claim 1 for use in the preparation of L-glufosinate or a salt thereof.

Citation Information

Patent Citations

  • CN1053669

  • Method for preparing L-glufosinate-ammonium by use of amino acid dehydrogenase

    CN106978453A

  • Method for preparing L-phosphinothricin through deracemization and by biological enzyme method

    CN107502647A

  • Glutamate dehydrogenase mutant and application of glutamate dehydrogenase mutant in preparation of L-glufosinate

    CN108588045A

  • Transaminase, preparation and use thereof

    EP0344683A2